<DOC>
	<DOCNO>NCT01752920</DOCNO>
	<brief_summary>This open-label , Phase 1/2 , dose escalation signal find study ARQ 087 administer subject advance solid tumor FGFR genetic alteration , include intrahepatic cholangiocarcinoma ( iCCA ) FGFR2 gene fusion . The study design explore safety , tolerability , pharmacokinetics , pharmacodynamics , preliminary efficacy ARQ 087 define RP2D ARQ 087 .</brief_summary>
	<brief_title>Phase 1/2 Study ARQ 087 Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>1 . Signed write informed consent grant 2 . Men woman ≥18 year age 3 . Histologically cytologically confirm , locally advanced , inoperable , metastatic solid tumor . Subjects eligible enrollment Expanded Cohort must document and/or confirm FGFR genetic alteration , include iCCA FGFR2 gene fusion . 4 . Failure respond standard therapy , standard therapy exist . 5 . Evaluable measurable disease 6 . Archival and/or fresh biopsy tissue sample must available prior first dose study drug 7 . Life expectancy ≥ 12 week 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 9 . Hemoglobin ( Hgb ) ≥ 9.0 g/dL 10 . Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L 11 . Platelet count ≥ 100 x 10^9/L 12 . Total bilirubin ≤ 1.5 × upper limit normal ( ULN ) ( ≤ 2 x ULN subject cholangiocarcinoma ) 13 . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3 × ULN ( ≤ 5 x ULN subject liver metastasis ) 14 . Serum creatinine ≤ 1.5 x ULN creatinine clearance &gt; 60 mL/min/1.73 m^2 subject creatinine level institutional normal 15 . Albumin ≥ 2.8 g/dL 16 . INR 0.8 ULN ≤ 3 subject receive anticoagulant therapy 17 . Men woman childproducing potential must agree use doublebarrier contraceptive measure , oral contraception , avoid intercourse study 90 day last dose study drug 18 . Women childbearing potential must negative serum pregnancy test Screening Period within 48 hour first dose ARQ 087 . 1 . Anticancer therapy , chemotherapy , immunotherapy , hormonal , targeted therapy , investigational agent within four week five time drug half life , whichever longer , first dose ARQ 087 2 . Major surgery radiation therapy within four week first dose ARQ 087 3 . Previous treatment FGFR inhibitor 4 . History allergic reaction attribute compound similar chemical biological composition ARQ 087 5 . Unable unwilling swallow complete daily dose ARQ 087 6 . Clinically unstable central nervous system ( CNS ) metastasis 7 . History myocardial infarction ( MI ) congestive heart failure define Class II IV per New York Heart Association classification within 6 month first dose ARQ 087 ( MI occur &gt; 6 month first dose ARQ 087 permit ) 8 . Significant GI disorder ( ) could interfere absorption , metabolism , excretion ARQ 087 ( e.g . Crohn 's disease , ulcerative colitis , extensive gastric resection ) 9 . History and/or current evidence clinically relevant ectopic mineralization/calcification 10 . Previous malignancy within 2 year prior first dose ARQ 087 , except curatively treat nonmelanoma skin cancer , carcinoma insitu breast cervix , superficial bladder tumor 11 . Known human immunodeficiency virus ( HIV ) infection 12 . Concurrent uncontrolled illness related cancer , include limited : Psychiatric illness/substance abuse/social situation would limit compliance study requirement . Uncontrolled diabetes mellitus 13 . Blood transfusion within 5 day blood draw use confirm eligibility 14 . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>FGFR</keyword>
	<keyword>ARQ 087</keyword>
	<keyword>Targeted therapy</keyword>
	<keyword>Molecular therapy</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
	<keyword>TKI</keyword>
	<keyword>Receptor tyrosine kinase</keyword>
	<keyword>RTK</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Phase I</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Liver Cancer</keyword>
	<keyword>Hepatobiliary carcinoma</keyword>
	<keyword>Biliary tract cancer</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Intrahepatic cholangiocarcinoma</keyword>
	<keyword>FGFR inhibitor</keyword>
	<keyword>Targeted FGFR kinase inhibitor</keyword>
	<keyword>Pan-FGFR inhibitor</keyword>
	<keyword>Selective FGFR inhibitor</keyword>
	<keyword>FGFR pathway</keyword>
	<keyword>FGFR signal</keyword>
	<keyword>Fibroblast growth factor</keyword>
	<keyword>FGFR1</keyword>
	<keyword>FGFR2</keyword>
	<keyword>FGFR3</keyword>
	<keyword>FGFR4</keyword>
	<keyword>FGF</keyword>
	<keyword>FGF19</keyword>
	<keyword>FGF21</keyword>
	<keyword>FGF23</keyword>
	<keyword>FGFR mutation</keyword>
	<keyword>FGFR gene fusion</keyword>
	<keyword>FGFR gene translocation</keyword>
	<keyword>FGFR genetic aberration</keyword>
	<keyword>FGFR2 fusion</keyword>
	<keyword>FGFR2 translocation</keyword>
	<keyword>Phase 1 Clinical Trial</keyword>
	<keyword>Phase I Clinical Trial</keyword>
	<keyword>Clinical oncology</keyword>
	<keyword>Tumor</keyword>
	<keyword>Tumour</keyword>
</DOC>